Impact of induction therapy with bortezomib, lenalidomide and dexamethasone vs. bortezomib, cyclophosphamide and dexamethasone on outcomes in patients with multiple myeloma undergoing stem cell transplantation.
Study #: MM19-01
Study Status: Published
Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation.
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A.
Transplantation and Cellular Therapy. 2022, Feb 03: 8(2): 8(2):e1-83.e9. doi: 10.1016/j.jtct.2021.10.022. Epub 2021, Nov 12. PMCID:PMC8900987.
PMID: 34781066
Abstract